# Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients

> **NCT04025450** · PHASE1,PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 50 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Chidamide+VRD
- **DRUG:** VRD

## Key facts

- **NCT ID:** NCT04025450
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-07-15
- **Primary completion:** 2029-07-15
- **Final completion:** 2029-07-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04025450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04025450, "Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04025450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*